GSK

See the following -

"Industry Will Not Support Open-Ended Science, So Govt Must"

Aradhna Wal | CNN-News18 | December 20, 2016

On December 11, News18 exposed how India’s clinical trials and drug discovery process is skewed towards diseases like cancer while ignoring the top killers of the country like TB, diarrhea and Kala Azar. Responding to that, Dr. Soumya Swaminathan, Director-General of the Indian Council for Medical Research (ICMR) told News18 there was a need to support indigenous research in India. In this interview to News18’s Aradhna Wal, Dr Swaminathan says India needs a 10-year vision on drug research...

Read More »

Approval Of A Coronavirus Vaccine Would Be Just The Beginning - Huge Production Challenges Could Cause Long Delays

The race for a SARS-CoV-2 vaccine is well underway. It's tempting to assume that once the first vaccine is approved for human use, all the problems of this pandemic will be immediately solved. Unfortunately, that is not exactly the case. Developing a new vaccine is only the first part of the complex journey that's supposed to end with a return to some sort of normal life. Producing hundreds of millions of vaccines for the U.S. - and billions for the world as a whole - will be no small feat. There are many technical and economic challenges that will need to be overcome somehow to produce millions of vaccines as fast as possible.

Read More »

Drug Giant Glaxo Pleads Guilty, Fined $3B for Drug Marketing

Staff Writer | USA Today | July 2, 2012

Drug giant GlaxoSmithKline will plead guilty and pay $3 billion to resolve federal criminal and civil inquiries arising from the company's illegal promotion of some of its products, its failure to report safety data and alleged false price reporting, the Justice Department announced Monday. Read More »

EU Agency Lifts Lid on Drug Data Secrets

Ben Hirschler | Reuters | July 15, 2012

Europe's medicines regulator, criticised in the past for excessive secrecy, is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information. Read More »

European Bioinformatics Institute (EMBL-EBI) ChEMBL 20 incorporates the Pistoia Alliance’s HELM annotation

Press Release | Pistoia Alliance, European Bioinformatics Institute | February 3, 2015

The European Bioinformatics Institute (EMBL-EBI) has released version 20 of ChEMBL, the database of compound bioactivity data and drug targets. ChEMBL now incorporates the Hierarchical Editing Language for Macromolecules (HELM), the macromolecular representation standard recently released by the Pistoia Alliance.

Read More »

Giant GSK Settlement Provides Reminder of the Pervasiveness of Stealth Marketing

Roy M. Poses | Health Care Renewal | July 5, 2012

The latest  and biggest legal settlement involving health care to hit the news, that of GlaxoSmithKline (GSK) and the US government, has many familiar elements. [These documents] provide good documentation about how pervasive systematic, deceptive stealth marketing campaigns have become in health care. Read More »

Open Source Drug Discovery Test A Success

Press Release | University Of Washington Health Sciences/UW Medicine | July 28, 2016

In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer...One-third of the labs reported their results in a paper published today in PLOS Pathogens, "Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond." The results have ignited more a dozen drug-development projects for a variety of diseases. "The trial was successful not only in identifying compounds to pursue for anti-malarials, but it also identified compounds to treat other parasites and cancer," said lead author Wesley Van Voorhis.

Read More »

Open Targets: New Name, New Data

Press Release | Wellcome Trust Sanger Institute, European Bioinformatics Institute | April 19, 2016

Following the successful launch of its Target Validation platform at the end of 2015, the Centre for Therapeutic Target Validation has released its first open experimental datasets. Now renamed Open Targets, the pioneering public–private initiative remains committed to speeding up the discovery of new medicines. Open Targets projects use genome-scale experiments and analysis to provide evidence on the biological validity of therapeutic targets – and to glean insights into the likely effectiveness of pharmacological intervention on these targets...

Read More »